222 related articles for article (PubMed ID: 20477997)
1. Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients.
Weclawiak H; Kamar N; Mengelle C; Esposito L; Mohamed AO; Lavayssiere L; Ribes D; Cointault O; Nogier MB; Cardeau-Desangles I; Izopet J; Rostaing L
Transpl Int; 2010 Oct; 23(10):1056-64. PubMed ID: 20477997
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients.
Wéclawiak H; Kamar N; Mengelle C; Guitard J; Esposito L; Lavayssière L; Cointault O; Ribes D; Rostaing L
J Med Virol; 2008 Jul; 80(7):1228-32. PubMed ID: 18461614
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
4. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
5. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
Kır O; Zeytinoğlu A; Arda B; Yılmaz M; Aşçı G; Töz H
Transplant Proc; 2017 Apr; 49(3):537-540. PubMed ID: 28340829
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
7. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2013 May; 57(1):50-3. PubMed ID: 23403239
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
9. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
11. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
14. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
[TBL] [Abstract][Full Text] [Related]
16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
[TBL] [Abstract][Full Text] [Related]
19. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
